What is the optimal hypertension management strategy for a patient with end‑stage renal disease?

Hypertension Management in ESRD Patients

For patients with end-stage renal disease on dialysis, target a systolic blood pressure <130 mmHg using standardized office measurements, prioritize aggressive volume management through dialysis prescription optimization (longer/more frequent sessions, lower dry weight targets), and initiate renin-angiotensin system inhibitors (ACEi/ARB) or calcium channel blockers as first-line pharmacotherapy while avoiding pre- and post-dialysis BP measurements for diagnosis or treatment decisions 1, 2.

Blood Pressure Measurement and Targets

Do not rely on peri-dialysis BP measurements—they are inaccurate and show spurious U-shaped mortality associations that reflect measurement error rather than true risk 3, 4. Instead:

• Use ambulatory BP monitoring (ABPM) as the gold standard for diagnosis and monitoring 3
• Home BP monitoring is an acceptable alternative when ABPM is unavailable 3
• Target office BP <130/80 mmHg using standardized measurement techniques 1

The KDIGO 2021 guidelines recommend a systolic target <120 mmHg for CKD patients when tolerated, but this applies to standardized office measurements and must be individualized in dialysis patients with symptomatic hypotension or very limited life expectancy 1.

Volume Management: The Foundation of Treatment

Volume overload is the primary driver of hypertension in ESRD—address this before escalating medications 2, 4.

For Hemodialysis Patients:

• Probe and lower the target dry weight gradually 2
• Increase dialysis time and/or frequency (consider home HD or nocturnal HD) 2
• Reduce interdialytic weight gain through dietary sodium restriction 2
• Improve hemodynamic stability during treatments 2

For Peritoneal Dialysis Patients:

• Maximize ultrafiltration using icodextrin for long dwells (day dwell in APD or overnight in CAPD) 2
• Use higher tonicity glucose solutions when needed, but minimize glucose load 2
• Shorten dwell times with glucose-based solutions in high transporters 2
• Preserve residual kidney function with diuretics when present 2
• Restrict dietary sodium 2

Pharmacologic Management

First-Line Agents

Start with ACE inhibitors or ARBs for patients with CKD stages G1-G4 and albuminuria 1. However, in dialysis patients specifically:

• ACEi/ARBs or calcium channel blockers are both appropriate first-line choices 1
• For kidney transplant recipients, use dihydropyridine CCBs or ARBs as first-line 1
• Beta-blockers warrant strong consideration as they reduce sympathetic overactivity, left ventricular hypertrophy, and may lower risk of arrhythmias and sudden cardiac death—major causes of mortality in dialysis patients 3

Dosing and Monitoring Considerations

When using RASi:

• Use the highest approved tolerated dose to achieve proven trial benefits 1
• Check BP, creatinine, and potassium within 2-4 weeks of initiation or dose increase 1
• Continue therapy unless creatinine rises >30% within 4 weeks 1
• Manage hyperkalemia with potassium-lowering measures rather than stopping RASi when possible 1
• Consider dose reduction or discontinuation only for symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or eGFR <15 mL/min with uremic symptoms 1

Dialyzability Matters

• ARBs are not dialyzable—dose once daily regardless of dialysis schedule 5
• ACE inhibitors are dialyzable—may require post-dialysis dosing 5
• CCBs are not dialyzable—provide consistent BP control 5
• Beta-blockers vary in dialyzability and cardioselectivity 5

Resistant Hypertension

After optimizing volume status, consider:

• Mineralocorticoid receptor antagonists (spironolactone, eplerenone)—effective but monitor closely for hyperkalemia, particularly with low eGFR 1, 3
• Clonidine or moxonidine for central sympathetic suppression 6, 5
• Direct vasodilators (hydralazine, minoxidil) may reduce left ventricular hypertrophy 5

Critical Contraindication

Never combine ACEi + ARB + direct renin inhibitor—this triple RAS blockade increases harm without benefit 1.

Common Pitfalls to Avoid

1. Do not use pre/post-dialysis BP alone for diagnosis or treatment decisions—these measurements are unreliable 3, 4
2. Do not apply the <120 mmHg target to non-standardized BP measurements—this is potentially hazardous 1
3. Do not escalate antihypertensives before optimizing volume status—you'll miss the primary problem 2, 4
4. Do not automatically discontinue RASi for mild creatinine or potassium elevations—use management strategies first 1
5. Do not overlook residual kidney function in PD patients—preserve it with diuretics and appropriate dialysate choices 2

Special Considerations

• In chronic hypotension: Consider switching from HD to PD, increase dialysis time, liberalize salt intake, reduce ultrafiltration volume, and withhold antihypertensives 2
• During peritonitis in PD patients: Expect altered peritoneal membrane function affecting ultrafiltration and BP control 6
• Emerging therapies like SGLT2 inhibitors show promise but require further safety evaluation in dialysis populations 6, 7